A Phase 2 combination study of Betalutin and rituximab in iNHL patients

Trial Profile

A Phase 2 combination study of Betalutin and rituximab in iNHL patients

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms ARCHER-1
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 22 Nov 2017 According to a Nordic Nanovector media release, the company is planning to start this trial in 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top